TLR9 and rheumatoid arthritis: By specifically engaging the extracellular domain of FcRL3, anti-FcRL3 antibodies have the potential to dampen activation of Toll-like receptors (e.g., TLR9), key mediators of immune responses implicated in autoantibody generation in RA [24].